Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure.

Eur J Heart Fail · 2020 · PMC7898542 · PMID 33251659

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

The 50% reduction in risk in EMPEROR‐Reduced was nominally significant, whereas the 29% decrease in risk in DAPA‐HF was not. 3 , 4 In contrast, the meta‐analysis of EMPEROR‐Reduced and EMPEROR‐Preserved is expected to yield >200 events, allowing a degree of precision in patients with chronic heart failure that approximates that seen in trials of patients with type 2 diabetes.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.